Have a feature idea you'd love to see implemented?
Let us know!
LCTX Lineage Cell Therapeutics Inc
Price (delayed)
$0.538
Market cap
$101.59M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.11
Enterprise value
$76.59M
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage's programs are based on its robust proprietary cell-based therapy platform and associated in-house
Highlights
The gross profit has grown by 47% from the previous quarter
The revenue has grown by 41% from the previous quarter
Lineage Cell Therapeutics's quick ratio has decreased by 9% YoY and by 6% QoQ
LCTX's equity is down by 3.1% QoQ and by 2.8% YoY
Key stats
What are the main financial stats of LCTX
Market
Valuations
Earnings
Shares outstanding
188.84M
Market cap
$101.59M
Enterprise value
$76.59M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.53
Price to sales (P/S)
11.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.78
Revenue
$8.72M
Gross profit
$8.28M
Net income
-$20.11M
EBIT
-$20.11M
EBITDA
-$19.48M
Free cash flow
-$23.06M
Per share
Balance sheet
Liquidity
EPS
-$0.11
EPS diluted
-$0.11
Free cash flow per share
-$0.12
Book value per share
$0.35
Revenue per share
$0.05
TBVPS
$0.21
Total assets
$96.59M
Total liabilities
$31.8M
Debt
$2.75M
Equity
$66.19M
Working capital
$20.54M
Debt to equity
0.04
Current ratio
2.48
Quick ratio
2.39
Net debt/EBITDA
1.28
Margins
Efficiency
Dividend
EBITDA margin
-223.4%
Gross margin
95%
Net margin
-230.7%
Operating margin
-260.7%
Return on assets
-19.7%
Return on equity
-29.8%
Return on invested capital
N/A
Return on capital employed
-24.3%
Return on sales
-230.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LCTX stock price
How has the Lineage Cell Therapeutics stock price performed over time
Intraday
-1.91%
1 week
8.27%
1 month
6.77%
1 year
-50.64%
YTD
-50.64%
QTD
-40.57%
Financial performance
How have Lineage Cell Therapeutics's revenue and profit performed over time
Revenue
$8.72M
Gross profit
$8.28M
Operating income
-$22.73M
Net income
-$20.11M
Gross margin
95%
Net margin
-230.7%
The gross profit has grown by 47% from the previous quarter
The revenue has grown by 41% from the previous quarter
The net margin has grown by 41% from the previous quarter and by 12% YoY
LCTX's operating margin is up by 37% since the previous quarter and by 9% year-on-year
Growth
What is Lineage Cell Therapeutics's growth rate over time
Valuation
What is Lineage Cell Therapeutics stock price valuation
P/E
N/A
P/B
1.53
P/S
11.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.78
LCTX's EPS is up by 15% since the previous quarter and by 15% year-on-year
LCTX's P/B is 51% below its last 4 quarters average of 3.1 and 45% below its 5-year quarterly average of 2.8
LCTX's equity is down by 3.1% QoQ and by 2.8% YoY
LCTX's price to sales (P/S) is 81% less than its 5-year quarterly average of 62.8 and 56% less than its last 4 quarters average of 26.2
The revenue has grown by 41% from the previous quarter
Efficiency
How efficient is Lineage Cell Therapeutics business performance
LCTX's ROS is up by 41% since the previous quarter and by 19% year-on-year
LCTX's return on equity is up by 16% since the previous quarter and by 8% year-on-year
Lineage Cell Therapeutics's ROA has increased by 15% from the previous quarter and by 3% YoY
Dividends
What is LCTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LCTX.
Financial health
How did Lineage Cell Therapeutics financials performed over time
LCTX's total liabilities is down by 19% year-on-year and by 11% since the previous quarter
LCTX's total assets is down by 9% year-on-year and by 6% since the previous quarter
The debt is 96% less than the equity
The debt to equity has contracted by 20% YoY
The debt has contracted by 11% YoY and by 7% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.